Glucagon-like Peptide-1 in Type 1 Diabetes

  • End date
    Jul 27, 2024
  • participants needed
  • sponsor
    University of Maryland, Baltimore
Updated on 27 April 2022


The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.


The naturally occurring hormone GLP-1 when co-administered during hypoglycemia (low blood sugar) in non-diabetic individuals can reduce the deleterious effects of hypoglycemia on the vasculature. We have shown that IV infusion of GLP-1 during a single moderate episode of hypoglycemia can preserve endothelial function and protect the vasculature from pro-coagulant and pro-inflammatory effects in healthy individuals.

It is unknown whether GLP-1 could protect the vasculature during episodes of repeated hypoglycemia and whether GLP-1 would have protective effects in T1DM individuals.

Condition Type1 Diabetes Mellitus
Treatment placebos, Glucagon-like Peptide-1
Clinical Study IdentifierNCT04355832
SponsorUniversity of Maryland, Baltimore
Last Modified on27 April 2022


Yes No Not Sure

Inclusion Criteria

(20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr
HbA1c < 11.0%
Body mass index < 40kg • m-2
No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)

Exclusion Criteria

Subjects unable to give voluntary informed consent
Subjects on anticoagulant drugs, anemic or with known bleeding diatheses
Subjects taking any of the following medications will be excluded: non-selective beta blockers
sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants
mood stabilizers, CNS stimulants, opioids, hallucinogens
Subjects unwillingness or inability to comply with approved contraception measures
Subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents
Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old
Hepatic failure /jaundice
Abnormal results following screening tests and physical examination that are clinically significant
Acute cerebrovascular/ neurological deficit
Fever greater than 38.0 C
Screening Laboratory Tests Exclusion Criteria
Hematocrit lower than 32
WBC lower than 3 thou/ul or greater than 14 thou/ul
Liver function tests: SGOT and SGPT greater than twice upper limit of normal range (i.e. > 80 U/L)
TBil > 2 mg/dl
Creatinine > 1.6 mg/dl
Alkaline phosphatase > 150U/L
Hepatic transaminase > 2x normal
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note